Literature DB >> 11669224

Invasive pneumococcal infections in Southwestern Sweden: a second follow-up period of 15 years.

M S Dahl1, B Trollfors, B A Claesson, L L Brandberg, A Rosengren.   

Abstract

In a retrospective study, the incidence, clinical manifestations, concomitant conditions and case fatality rate were studied in patients with invasive pneumococcal infections in the Göteborg area of Sweden during 1981-95, when the pneumococcal polysaccharide vaccine was available but little used. Patients were identified from the records of the Departments of Clinical Bacteriology and from the computer-based hospital discharge registers of the relevant departments. Individual case records were found for 876 patients with invasive pneumococcal infections verified by cultures from blood, cerebrospinal fluid or other sterile body fluids. A study from the same area with the same design covering the years 1964-80 has previously been published. There was an increase in total incidence from 5.3 to 10.3 cases/100,000/y from the previous to the present study. This increase was due to an increase in patients with non-meningitic infections aged > or = 60 y. The incidence of meningitis was virtually unchanged (1.4/100,000/y), as was the incidence of non-meningitic infections in individuals < 60 y. There were no other important changes between the 2 studies, which confirm that invasive pneumococcal infections have the highest incidence rates in children < 2 y and in the elderly, that a wide variety of underlying conditions are seen in the patients and that the case fatality rate, 15% in the present study, is still high.

Entities:  

Mesh:

Year:  2001        PMID: 11669224     DOI: 10.1080/00365540110026818

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  8 in total

1.  Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.

Authors:  M A Julie Westerink; Harry W Schroeder; Moon H Nahm
Journal:  Aging Dis       Date:  2011-07-20       Impact factor: 6.745

2.  Race-related differences in functional antibody response to pneumococcal vaccination in HIV-infected individuals.

Authors:  Myroslawa Happe; Devadoss J Samuvel; Jennifer A Ohtola; Jeff E Korte; M A Julie Westerink
Journal:  Vaccine       Date:  2019-02-21       Impact factor: 3.641

3.  Burden of paediatric invasive pneumococcal disease in Europe, 2005.

Authors:  E D G McIntosh; B Fritzell; M A Fletcher
Journal:  Epidemiol Infect       Date:  2006-09-07       Impact factor: 2.451

Review 4.  Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

Authors:  Katelijne van de Vooren; Silvy Duranti; Alessandro Curto; Livio Garattini
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

5.  Bacteremia with Streptococcus pneumoniae: sepsis and other risk factors for 30-day mortality--a hospital-based cohort study.

Authors:  J S Christensen; T G Jensen; H J Kolmos; C Pedersen; A Lassen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-13       Impact factor: 3.267

6.  Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors.

Authors:  Erik Backhaus; Stefan Berg; Rune Andersson; Gunilla Ockborn; Petter Malmström; Mats Dahl; Salmir Nasic; Birger Trollfors
Journal:  BMC Infect Dis       Date:  2016-08-03       Impact factor: 3.090

7.  International Circumpolar Surveillance System for invasive pneumococcal disease, 1999-2005.

Authors:  Michael G Bruce; Shelley L Deeks; Tammy Zulz; Dana Bruden; Christine Navarro; Marguerite Lovgren; Louise Jette; Karl Kristinsson; Gudrun Sigmundsdottir; Knud Brinkløv Jensen; Oistein Lovoll; J Pekka Nuorti; Elja Herva; Anders Nystedt; Anders Sjostedt; Anders Koch; Thomas W Hennessy; Alan J Parkinson
Journal:  Emerg Infect Dis       Date:  2008-01       Impact factor: 6.883

8.  Invasive pneumococcal disease in persons with predisposing factors is dominated by non-vaccine serotypes in Southwest Sweden.

Authors:  Karin Bergman; Tor Härnqvist; Erik Backhaus; Birger Trollfors; Mats S Dahl; Helena Kolberg; Gunilla Ockborn; Rune Andersson; Johanna Karlsson; Åsa Mellgren; Susann Skovbjerg
Journal:  BMC Infect Dis       Date:  2021-08-04       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.